<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Hypocellular <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) represents only a small portion of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, of which, the clinical significance has not been well-defined </plain></SENT>
<SENT sid="1" pm="."><plain>By using currently accepted age-adjusted criteria to define hypocellularity as &lt;30% in patients &lt;70 years old, and &lt;20% in &gt;70 years old, we identified 163 (15.5%) hypocelluar <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> from 1049 consecutive adult <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients over an 11-year period (1995-2006) </plain></SENT>
<SENT sid="2" pm="."><plain>Compared to <z:mpath ids='MPATH_458'>normal</z:mpath>/hypercellular <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, hypocellular <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients were younger (p&lt;0.01), less anemic (p=0.02), but more neutropenic (p&lt;0.001) and thrombocytopenic (p=0.05), and had a comparable cytogenetic risk group distribution (p=0.09) and international prognostic scores (IPSS, p=0.13) </plain></SENT>
<SENT sid="3" pm="."><plain>With a median follow-up of 52 months, hypocellular <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> showed a favorable overall survival (56 months versus 28 months, log-rank p&lt;0.0001) over <z:mpath ids='MPATH_458'>normal</z:mpath>/hypocellular <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, and this survival preference was also demonstrated in <z:hpo ids='HP_0000001'>all</z:hpo> IPSS groups and cytogenetic risk groups, and was independent of <z:hpo ids='HP_0000001'>all</z:hpo> other risk factors (Cox regression test, p=0.01) </plain></SENT>
<SENT sid="4" pm="."><plain>In conclusion, our study demonstrated that hypocellular <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> has characteristic clinicopathologic features, and <z:hpo ids='HP_0005528'>bone marrow hypocellularity</z:hpo> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> is an independent factor which predicts a favorable outcome </plain></SENT>
</text></document>